MS143 (75 mg/kg; i.p., 22 days) drastically inhibits the tumor growth by 92%, also substantially degrades T-AKT and P-AKT, and effectively inhibits the downstream signaling (PRAS40 phosphorylation) in xenograft mice[1].
Pharmacokinetic Parameters of MS143 in male Swiss Albino mice[1].
| IP (75 mg/kg) |
| Cmax (μM) | 7 |
| Tmax (h) | 2 |
| AUC0-12 (h·ng/mL) | 63600 |
| Animal Model: | Male immunocompromised NU/J mice (6 weeks old)[1] |
| Dosage: | 75 mg/kg |
| Administration: | i.p., 22 days |
| Result: | Drastically inhibited the tumor growth by 92%, also substantially degraded T-AKT and P-AKT, and effectively inhibited the downstream signaling (PRAS40 phosphorylation). |
